Search Results
Sep 08, 2026, 10:19 ET Pharmaceutical CDMO Market to Reach US$ 270.3 Bn by 2031, Growing at 7.2% CAGR, New Report by Wissen Research
products. At the same time, rising demand for complex drug classes — including biologics, cell and gene therapies, antibody-drug conjugates (ADCs), and mRNA-based medicines — is pushing CDMOs to build out increasingly specialized manufacturing platforms and analytics capabilities. As outsourcing becomes
More news about: Wissen Research LLC
Sep 08, 2026, 04:05 ET /C O R R E C T I O N -- GCCL/
services across the Asia-Pacific region.The company engaged with drug developers working across a broad range of therapeutic modalities, including mRNA and nucleic acid therapeutics, radiopharmaceuticals and antibody-based therapies. These discussions focused on evolving analytical requirements in global
More news about: GCCL
Sep 04, 2026, 02:00 ET Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026
2. Current treatments require frequent dosing, highlighting the need for long-acting, preventive therapies. BW-20805 targets human hepatic PKK mRNA to inhibit PKK gene expression, offering the potential for effective prevention of HAE attacks with a significant and longer-lasting therapeutic effect.About
More news about: Argo Biopharmaceutical Co., Ltd
Sep 02, 2026, 17:00 ET Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Sep 02, 2026, 09:00 ET Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines
payload mRNA to make the R2 protein and a second RNA containing the therapeutic gene flanked by sequences to recruit the R2 protein. Inside the cell, the two assemble into an active complex that inserts the gene into the specific target site by TPRT. The R2 machinery then degrades along with the mRNA, leaving
More news about: Typewriter Therapeutics, Inc.
Sep 02, 2026, 09:00 ET New Johns Hopkins Study Identifies Pervasive RT-qPCR Artifact in CRISPR Knockdown Studies and How UltraMarathonRT® Solves It
Guide RNAs from RNA-targeting CRISPR systems remain bound to their target mRNA after total RNA preparations and suppress conventional reverse transcription. uMRT's strand-displacing reverse transcriptase restores accurate knockdown quantification.BRANFORD,
More news about: RNAConnect
Sep 02, 2026, 07:00 ET Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing
the early and expansion stages. Since 2019, it has backed ten companies spanning modalities including PDCs, large molecules, cell and gene therapy, mRNA/LNP, siRNA, and small molecules, with a 12-project clinical-stage pipeline across anti-infectives, oncology, regenerative medicine, ophthalmology, otology,
More news about: Raziel Therapeutics; Fosun Pharma
Aug 31, 2026, 01:00 ET Samsung Biologics publishes prospectus for PolyPeptide public tender offer
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Aug 28, 2026, 08:30 ET Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
challenge, particularly among older adults and high-risk populations1Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients
More news about: Novavax, Inc.
Aug 28, 2026, 07:00 ET CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene
next-generation mRNA therapeutics. The company has developed proprietary LNP delivery platforms and RNA engineering technologies to enable applications across oncology, autoimmune diseases, infectious diseases, metabolic disorders, and in vivo cell therapies. The company's lead mRNA asset, WGc-043,
More news about: CREATE Medicines, Inc.
Aug 28, 2026, 03:00 ET Evonik baut Produktionskapazitäten für lipidbasierte Wirkstoffe in Vancouver aus
wegweisender Pionier. Lipide spielen eine entscheidende Rolle bei der Verkapselung und gezielten Freisetzung nukleinsäurebasierter Wirkstoffe, einschließlich mRNA, sowie anderer aktiver Substanzen. Lipid-Nanopartikel (LNPs) haben sich als führende Technologie für die Wirkstoffabgabe etabliert, wie ihre zentrale
More news about: Evonik Industries AG
Aug 28, 2026, 03:00 ET Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
market is projected to grow to $2.7 billion by 2034Lipids are essential for encapsulating and delivering nucleic acid-based drugs, including mRNA, as well as other payloads. LNPs have become a leading delivery system, underscored by their role in COVID-19 vaccines, and demand continues to grow
More news about: Evonik Industries AG
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
trials across respiratory and autoimmune indications. AK150, an ILT2/ILT4/CSF1R trispecific antibody, is in Phase I development. AK154, a personalized mRNA cancer vaccine that leverages AI-powered selection of high-affinity immunogenic mutations to create precision oncology therapies. A Phase I study of
More news about: Akeso, Inc.
Aug 27, 2026, 18:58 ET Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes,
More news about: Samsung Biologics
Aug 27, 2026, 15:17 ET Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
market is projected to grow to $2.7 billion by 2034Lipids are essential for encapsulating and delivering nucleic acid-based drugs, including mRNA, as well as other payloads. LNPs have become a leading delivery system, underscored by their role in COVID-19 vaccines, and demand continues to grow
More news about: Evonik Industries AG
Aug 27, 2026, 07:32 ET African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials
partnerships just two weeks after the declaration of the outbreak in mid-May. CEPI has to date already invested in Bundibugyo vaccines being developed using mRNA (Moderna), ChAdOx (the University of Oxford/ Serum Institute of India) and rVSV (IAVI with manufacturing by Hilleman Laboratories, and Public Health
More news about: Minapharm Pharmaceuticals
Aug 27, 2026, 07:27 ET African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials
partnerships just two weeks after the declaration of the outbreak in mid-May. CEPI has to date already invested in Bundibugyo vaccines being developed using mRNA (Moderna), ChAdOx (the University of Oxford/ Serum Institute of India) and rVSV (IAVI with manufacturing by Hilleman Laboratories, and Public Health
More news about: Minapharm Pharmaceuticals
Aug 26, 2026, 09:00 ET ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth Disease
VoyageR AI platform and is designed to modulate the integrated stress response (ISR) pathway. By activating eIF2B, RTX-117 is intended to restore normal mRNA translation and protein-expression homeostasis. ReviR is advancing the program in CMT while expanding its translational research in ISR-related diseases,
More news about: ReviR Therapeutics
Aug 26, 2026, 06:37 ET Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026
submitted to peer-reviewed journals. Concurrently, the Company participated in the investment of Yuanma Therapeutics to co-build the next-generation mRNA AI-native R&D engine.By strategically laying out AI agents, vertical foundation models, model evaluation, cloud computing power, and industrial
More news about: Insilico Medicine
Aug 26, 2026, 02:15 ET 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing
produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping
More news about: Genezen
Aug 25, 2026, 17:00 ET Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Aug 25, 2026, 09:15 ET /C O R R E C T I O N -- Akeso, Inc./
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Aug 24, 2026, 03:01 ET ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
collaborative research and co-development to identify CNS-targeted drug candidates by utilizing LNP technologies with various modalities, including mRNA, siRNA, and ASO. We are already receiving interest from global companies and are currently discussing collaborative research with multiple companies.""We
More news about: ImmunoForge Co., Ltd.
Aug 21, 2026, 05:28 ET China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
field, Beijing-based Likang Life Sciences is among the more clinically advanced developers in China's personalized mRNA cancer vaccine sector.Clinical Development of Personalized mRNA Cancer Vaccines Accelerates in ChinaIn 2023, LK101, developed by Likang Life Sciences, received clinical
More news about: Likang Life Sciences
Aug 20, 2026, 19:10 ET Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
BRII-5395, an internally discovered mRNA therapeutic vaccine for advanced hepatocellular carcinoma (HCC). This milestone represents the first clinical evaluation of an RNA-based therapeutic originating from Brii Bio's internal discovery efforts. While BRII-5395 is an mRNA therapeutic vaccine, the Company's
More news about: Brii Biosciences Limited